MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
Vivos Therapeutics Total Assets 2011-2026 | VVOS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Vivos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.2 M | 15.3 M | 10.7 M | 13.7 M | 33.7 M | 25.3 M | 7.55 M | 8.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.7 M | 7.55 M | 17.5 M |
Quarterly Total Assets Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.6 M | 26 M | 11.3 M | 15.3 M | 15.3 M | 15.8 M | 11.8 M | 10.7 M | 10.3 M | 13.7 M | - | 13.7 M | 18.4 M | 24.4 M | 29.6 M | 33.7 M | 41 M | 33.7 M | 22 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 7.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41 M | 7.55 M | 20.9 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
6.21 B | $ 190.07 | 2.73 % | $ 14.2 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.66 | 0.64 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.49 | -2.79 % | $ 131 M |  France |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 64.23 | 1.28 % | $ 95.1 B | USA |
 |
Electromed
ELMD
|
53.8 M | $ 26.06 | 2.64 % | $ 220 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.66 | 8.2 % | $ 41.1 M | USA |
 |
ClearPoint Neuro
CLPT
|
97.7 M | $ 11.79 | 12.29 % | $ 334 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.75 | 1.33 % | $ 393 M | USA |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
LENSAR
LNSR
|
71.4 M | $ 5.93 | 2.24 % | $ 70.9 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
5.3 B | $ 95.25 | 2.7 % | $ 12.9 B | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.12 | 2.91 % | $ 1.29 M | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 5.45 | 3.02 % | $ 1.15 B | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
299 M | $ 6.82 | 3.49 % | $ 181 M | USA |
 |
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.06 | 1.92 % | $ 18 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
124 M | $ 10.86 | 0.28 % | $ 389 M | USA |
 |
Inspire Medical Systems
INSP
|
907 M | $ 57.59 | 2.02 % | $ 1.69 B | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 39.08 | 3.09 % | $ 1.21 B | USA |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 67.12 | 3.25 % | $ 3.66 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
3.41 B | $ 90.2 | 2.07 % | $ 3.13 B | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.8 | 0.21 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 80.99 | 2.45 % | $ 47.4 B | USA |
 |
Sintx Technologies
SINT
|
9.51 M | $ 2.7 | 0.75 % | $ 7.49 M | USA |
 |
Penumbra
PEN
|
1.83 B | $ 332.13 | 0.2 % | $ 12.9 B | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |